ALVO
Alvotech
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IS
$5.03
+0.60%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$5.13
From 52W high−42.32%
Volume907010.00
Market cap$1.79B
P/E (TTM)—
P/S (TTM)3.6x
Div yield—
Key dataOct 19, 2026
Open
$5.13
From 52W high
−42.32%
Volume
907010.00
Market cap
$1.79B
ValuationView details →
P/E (Fwd)
21.4x
EV/EBITDA
475.1x
P/E (TTM)
—
RSI (14)
43.0
MomentumView details →
1D Return
+0.60%
YTD Return
−0.88%
SummaryUpdated Jun 1, 2026
Alvotech (NASDAQ:ALVO) is an Iceland-based biotechnology company founded in 2013 that specializes in developing and manufacturing biosimilar medicines. The company went public in June 2022 and has invested approximately $2 billion over more than a decade to build a vertically integrated biosimilar platform. Alvotech operates globally with commercial reach extending to over 90 countries and maintains its headquarters in Reykjavik, Iceland, with additional operations including recent acquisitions in Sweden.
Similar companies
Latest newsMore news →
Alvotech and Advanz Pharma Corp. Ltd. announced that AVT29 was submitted to the EUROPEAN MEDICINES AGENCY as a line extension to the existing marketing authorization for Mynzepli (aflibercept 2 mg).6d agoAlvotech and Lotte Biologics Co., Ltd. announced a long-term manufacturing partnership under which Lotte Biologics Co., Ltd. will produce drug substance for multiple Alvotech antibody biosimilar products at its Syracuse, New York facility for global supply.13d agoThe FDA approved additional U.S. manufacturing capacity allowing Alvotech's SIMLANDI (AVT02) drug substance to be produced in either of its two Reykjavik drug substance suites.15d ago